Cozen O’Connor Represents Albaron Partners in First Private Equity Exit in U.S. Podiatry

Tuesday, January 9, 2024

PHILADELPHIA, January 9, 2024 — Cozen O’Connor advised Albaron Partners, a middle-market private equity firm focused on founder-led health care companies, in its sale of Albaron Podiatry Holdings LLC d/b/a Beyond Podiatry, a leader in the management of podiatric medicine in the Midwest, to CUC Inc. The deal represents the first private equity exit in U.S. podiatry history.

The transaction, which closed on January 5, 2024, and valued the business at $87 million, resulted in a 100% cash exit for Albaron Partners. The deal marked the first U.S. acquisition for CUC Inc.

The Cozen O’Connor team was led by Anna M. McDonough and included David S. Nelson, Marco Biagiotti, James W. Forsyth, Eric Huang, Robert S. Kaplan, Danielle E. Sapega, and Christopher R. Raphaely.

Cozen O’Connor’s Corporate Practice provides sophisticated counsel to a diverse set of businesses and entrepreneurs ranging from Fortune 500 and other multinational companies to middle-market businesses. The firm’s corporate attorneys assist clients from a wide range of industries in issues related to corporate governance, mergers and acquisitions, tax, securities, and finance.

About Cozen O’Connor

Established in 1970, Cozen O’Connor has more than 925 attorneys who help clients manage risk and make better business decisions. The firm counsels clients on their most sophisticated legal matters in all areas of the law, including litigation, corporate, and regulatory law. Representing a broad array of leading global corporations and middle market companies, Cozen O’Connor services its clients’ needs through 33 offices across two continents.

Share on LinkedIn

People

Related Practice Areas

Keep up-to-date with the latest news from Cozen O'Connor

Enter your City or Zip.

Probably shouldn't change this:
Sign up to receive alerts, publications, and event / webinar invites.

By submitting your contact information, you are giving Cozen O'Connor consent to contact you via email.